

jp2005524730/pn

L1 ANSWER 1 OF 1 WPINDEX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-070998 [07] WPINDEX
DOC. NO. CPI: C2004-029315 [07]
TITLE: New diblock copolymer used to prepare composition for
the manufacture of pharmaceutical dosage form for oral or
parenteral administration to human or non-human animal
DERWENT CLASS: A23; A25; A96; B07
INVENTOR: ARIEN A M E; ARIEN A M E; BREWSTER M E; NATHAN A;
OULD-OUALI L M; PREAT V; ROSENBLATT J
PATENT ASSIGNEE: (JANC-C) JANSSEN PHARM NV; (ARIE-I) ARIEN A M E; (BREW-
I) BREWSTER M E; (NATH-I) NATHAN A; (OULD-I) OULD-OUALI L
M;
(PREA-I) PREAT V; (ROSE-I) ROSENBLATT J
COUNTRY COUNT: 103

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2003093344	A1	20031113	(200407)*	EN	46.[0]	C08G063-06
AU 2003222310	A1	20031117	(200442)	EN		
EP 1504047	A1	20050209	(200512)	EN		
BR 2003009688	A	20050222	(200517)	PT		
NO 2004005283	A	20050107	(200523)	NO		C08G063-08
KR 2004111466	A	20041231	(200528)	KO		C08G063-08
NZ 536294	A	20050527	(200537)	EN		
JP 2005524730	W	20050818	(200555)	JA	40	C08G085-00 <-
MX 2004010778	A1	20050301	(200568)	ES		A61K047-10
CN 1649932	A	20050803	(200578)	ZH		C08G063-06
TW 2004013434	A	20040801	(200581)	ZH		C08G063-06
ZA 2004008854	A	20060125	(200611)	EN	57	C08G000-00
US 20060034797	A1	20060216	(200614)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003093344	A1	WO 2003-EP4368	20030424
AU 2003222310	A1	AU 2003-222310	20030424
BR 2003009688	A	BR 2003-9688	20030424
CN 1649932	A	CN 2003-809579	20030424
EP 1504047	A1	EP 2003-717321	20030424
NZ 536294	A	NZ 2003-536294	20030424
EP 1504047	A1	WO 2003-EP4368	20030424
BR 2003009688	A	WO 2003-EP4368	20030424
NO 2004005283	A	WO 2003-EP4368	20030424
NZ 536294	A	WO 2003-EP4368	20030424
JP 2005524730	W	***WO 2003-EP4368	20030424***
MX 2004010778	A1	WO 2003-EP4368	20030424
TW 2004013434	A	TW 2003-112064	20030502
JP 2005524730	W	***JP 2004-501483	20030424***
KR 2004111466	A	KR 2004-715633	20041001
MX 2004010778	A1	MX 2004-10778	20041029
ZA 2004008854	A	ZA 2004-8854	20041102
NO 2004005283	A	NO 2004-5283	20041202

US 20060034797 A1
US 20060034797 A1

WO 2003-EP4368 20030424
US 2005-522456 20050121

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003222310 A1	Based on	WO 2003093344 A
EP 1504047 A1	Based on	WO 2003093344 A
BR 2003009688 A	Based on	WO 2003093344 A
NZ 536294 A	Based on	WO 2003093344 A
JP 2005524730 W	Based on	WO 2003093344 A
MX 2004010778 A1	Based on	WO 2003093344 A

PRIORITY APPLN. INFO: US 2002-377901P 20020503

INT. PATENT CLASSIF.:

MAIN: A61K047-10; C08G; C08G063-06; C08G063-08; C08G085-00
SECONDARY: A61K; A61K047-34; A61K009-08; A61K009-107; C08G063-48;
C08G063-58; C08G063-64; C08G063-91; C08G064-02;
C08G064-18; C08G065-08; C08G065-329; C08L; C08L069-00
IPC ORIGINAL: A61K0031-74 [I,C]; A61K0031-765 [I,A]; C08K0005-00
[I,C];
C08K0005-07 [I,A]

BASIC ABSTRACT:

WO 2003093344 A1 UPAB: 20060203

NOVELTY - A diblock copolymer, which is liquid below 50degreesC
is
new.

DETAILED DESCRIPTION - A diblock copolymer of formula A-B and is
liquid below 50degreesC is new.

A = linear pharmaceutically acceptable hydrophilic polymer;

B = polymer comprising monomers consisting of L-lactic acid,
D-lactic acid, D,L-lactic acid, glycolic acid, propiolactone,
gamma-butyrolactone, delta-valerolactone, gamma-valerolactone,
epsilon-caprolactone, trimethylene carbonate, p-dioxane, tetramethylene
carbonate, epsilon-lactone, and/or 1,5-dioxepan-2-one.

INDEPENDENT CLAIMS are also included for:

(a) a non-aqueous composition comprising an active ingredient
and
the above diblock copolymer(s);

(b) a pharmaceutical dosage form comprising the non-aqueous
composition;

(c) preparation of an aqueous solution by mixing an active
ingredient with the above diblock copolymer at below 50degreesC, and
adding water while stirring; and

(d) a pharmaceutical package for commercial scale comprising a
container, pharmaceutical dosage form, and an associated package
written
matter.

USE - Used to form a composition for the manufacture of
pharmaceutical dosage form for oral or parenteral administration to a
human or non-human animal.

ADVANTAGE - The inventive diblock copolymers are self-
emulsifying,
thus increasing the solubility and bioavailability of poorly water
soluble drugs.

MANUAL CODE: CPI: A12-V; A12-V01; B04-C03C; B04-C03D; B11-C06; B12-
M07